Amedeo Smart

Free Medical Literature Service

 

Amedeo

Gynecology
  Free Subscription

Articles published in
Cancer
    November 2024
  1. NIERENGARTEN MB
    Common strategy to diagnose endometrial cancer may not be reliable for Black women.
    Cancer. 2024;130:3783.
    >> Share

  2. NIERENGARTEN MB
    Women with more severe forms of endometriosis have a nearly 10-fold higher risk of ovarian cancer.
    Cancer. 2024;130:3784.
    >> Share

    October 2024
  3. KONDO T, Matsuki E, Takaku T, Watanabe N, et al
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors.
    Cancer. 2024 Oct 30. doi: 10.1002/cncr.35611.
    >> Share

  4. JOHNSON HM, Song J, Warneke CL, Martinez AL, et al
    Outcomes of patients treated with chemotherapy for breast cancer during pregnancy compared with nonpregnant breast cancer patients treated with systemic therapy.
    Cancer. 2024 Oct 29. doi: 10.1002/cncr.35619.
    >> Share

  5. WILSON EM, Huang R, Jones KD, Hagemann IS, et al
    Challenges in implementation of molecular classification in early stage endometrial cancer-An NRG Oncology cooperative group mixed-methods study.
    Cancer. 2024 Oct 17. doi: 10.1002/cncr.35596.
    >> Share

  6. NIERENGARTEN MB
    Excellent outcomes with radiation alone for localized recurrences of endometrial cancer.
    Cancer. 2024;130:3400.
    >> Share

    September 2024
  7. MEGHANI K, Grover S
    Reply to "Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary".
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35553.
    >> Share

  8. JEYARAJ G
    Assessing the impact of HIV status on cervical cancer treatment outcomes in Botswana: A commentary.
    Cancer. 2024 Sep 10. doi: 10.1002/cncr.35545.
    >> Share

    August 2024
  9. SULLIVAN MW, Graves S, Adkoli A, Zhou Q, et al
    Factors associated with an inconclusive result from commercial homologous recombination deficiency testing in ovarian cancer.
    Cancer. 2024 Aug 16. doi: 10.1002/cncr.35523.
    >> Share

  10. ISSAKA RB, Ibekwe LN, Todd KW, Burnett-Hartman AN, et al
    Association between racial residential segregation and screening uptake for colorectal and cervical cancer among Black and White patients in five US health care systems.
    Cancer. 2024 Aug 9. doi: 10.1002/cncr.35514.
    >> Share

    July 2024
  11. PEREZ L, Dioun S, Primiano M, Blank SV, et al
    Considering screening for hereditary cancer syndromes at the time of obstetrical prenatal carrier screening.
    Cancer. 2024 Jul 22. doi: 10.1002/cncr.35480.
    >> Share

  12. MACKAY H, Fernandes I
    Cell-free DNA in recurrent and metastatic endometrial cancer: The future is now? Promises and potential pitfalls.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35448.
    >> Share

  13. ELGHAZALY H, Azim HA, Rugo HS, Cameron D, et al
    Tailoring neo/adjuvant systemic therapy in breast cancer: "The advent of a personalized approach"-The Breast-Gynecological and Immuno-Oncology International Cancer Conference (BGICC) consensus and recommendations.
    Cancer. 2024 Jul 10. doi: 10.1002/cncr.35389.
    >> Share

  14. BANERJEE S, Hasson SP
    Top advances of the year: Immunotherapy in endometrial cancer.
    Cancer. 2024 Jul 4. doi: 10.1002/cncr.35417.
    >> Share

  15. NIERENGARTEN MB
    Significant overall survival benefit with dostarlimab plus chemotherapy in advanced endometrial cancer.
    Cancer. 2024;130:2245.
    >> Share

  16. NIERENGARTEN MB
    Favorable overall survival trend with pembrolizumab plus chemotherapy for endometrial cancer.
    Cancer. 2024;130:2246.
    >> Share

    June 2024
  17. BEAVIS AL, Wethington SL, Yu R, Topel KM, et al
    Differential utilization of the online patient portal for completion of health-related social needs screening during routine gynecologic cancer care.
    Cancer. 2024 Jun 29. doi: 10.1002/cncr.35376.
    >> Share


  18. Erratum to "Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: A combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials".
    Cancer. 2024 Jun 7. doi: 10.1002/cncr.35344.
    >> Share

  19. BLANC-DURAND F, Camilleri GM, Bayle A, Aldea M, et al
    Clinical utility of comprehensive liquid molecular profiling in patients with advanced endometrial cancer.
    Cancer. 2024 Jun 2. doi: 10.1002/cncr.35381.
    >> Share

    May 2024
  20. LOGGERS ET, Chugh R, Federman N, Hartner L, et al
    Onset and resolution of ovarian toxicity with nirogacestat treatment in females with desmoid tumors: Updated safety analyses from the DeFi phase 3 study.
    Cancer. 2024 May 4. doi: 10.1002/cncr.35324.
    >> Share

    April 2024
  21. DUSKA LR, Podwika SE, Randall LM
    Top advances of the year: Cervical cancer.
    Cancer. 2024 Apr 23. doi: 10.1002/cncr.35334.
    >> Share

  22. STERPETTI AV, Gabriele R, Iannone I, Dimarzo L, et al
    National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough.
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35335.
    >> Share

  23. RUAN Y, Heer E, Brenner DR
    Reply to "National organized screening programs for breast, colorectal, and cervical cancer reduce socioeconomic disparities, but it is not enough".
    Cancer. 2024 Apr 20. doi: 10.1002/cncr.35339.
    >> Share

  24. NIERENGARTEN MB
    Promising new treatment approaches for locally advanced cervical cancer.
    Cancer. 2024;130:1192.
    >> Share

  25. ERICKSON BK, Slomovitz B, Powell M, Eskander RN, et al
    Top advances of the year: Uterine cancer.
    Cancer. 2024 Apr 15. doi: 10.1002/cncr.35321.
    >> Share

    March 2024
  26. MEGHANI K, Puri P, Bazzett-Matabele L, Vuylsteke P, et al
    Significance of HIV status in cervical cancer patients receiving curative chemoradiation therapy, definitive radiation alone, or palliative radiation in Botswana.
    Cancer. 2024 Mar 26. doi: 10.1002/cncr.35289.
    >> Share

  27. LEE H, Baeker Bispo J, Pal Choudhury P, Wiese D, et al
    Factors contributing to differences in cervical cancer screening in rural and urban community health centers.
    Cancer. 2024 Mar 25. doi: 10.1002/cncr.35265.
    >> Share

  28. MICHEL AD, Fontenot HB, Fuzzell L, Brownstein NC, et al
    Attitudes toward the American Cancer Society's 2020 cervical cancer screening guidelines: A qualitative study of a national sample of US clinicians.
    Cancer. 2024 Mar 4. doi: 10.1002/cncr.35269.
    >> Share

    February 2024
  29. LIU YL, Weigelt B
    A tale of two pathways: Review of immune checkpoint inhibitors in DNA mismatch repair-deficient and microsatellite instability-high endometrial cancers.
    Cancer. 2024 Feb 29. doi: 10.1002/cncr.35267.
    >> Share

  30. YANG EH, Strohl HB, Su HI
    Fertility preservation before and after cancer treatment in children, adolescents, and young adults.
    Cancer. 2024;130:344-355.
    >> Share

    January 2024
  31. MUTCH D, Voulgari A, Chen XM, Bradley WH, et al
    Primary results and characterization of patients with exceptional outcomes in a phase 1b study combining PARP and MEK inhibition, with or without anti-PD-L1, for BRCA wild-type, platinum-sensitive, recurrent ovarian cancer.
    Cancer. 2024 Jan 30. doi: 10.1002/cncr.35222.
    >> Share

  32. FLOREZ N, Kaufman RA, Yanez-Sarmiento A, Abioye O, et al
    When the unimaginable happens: Lung cancer diagnosis during pregnancy.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35227.
    >> Share

  33. BYRD DA, Zouiouich S, Karwa S, Li XS, et al
    Associations of serum trimethylamine N-oxide and its precursors with colorectal cancer risk in the Prostate, Lung, Colorectal, Ovarian Cancer Screening Trial Cohort.
    Cancer. 2024 Jan 29. doi: 10.1002/cncr.35219.
    >> Share


  34. New test for detecting cervical adenocarcinoma.
    Cancer. 2024;130:10.
    >> Share

  35. BYTNAR JA, McGlynn KA, Nealeigh MD, Shriver CD, et al
    Cancer incidence in the US military: An updated analysis.
    Cancer. 2024;130:96-106.
    >> Share

    December 2023
  36. RIMEL BJ, Enserro D, Bender DP, Jackson CG, et al
    NRG-GY012: Randomized phase 2 study comparing olaparib, cediranib, and the combination of cediranib/olaparib in women with recurrent, persistent, or metastatic endometrial cancer.
    Cancer. 2023 Dec 21. doi: 10.1002/cncr.35151.
    >> Share

  37. LUMISH MA, Kohn EC, Tew WP
    Top advances of the year: Ovarian cancer.
    Cancer. 2023 Dec 15. doi: 10.1002/cncr.35135.
    >> Share

    November 2023
  38. HINCHCLIFF EM, Knisely A, Adjei N, Fellman B, et al
    Randomized phase 2 trial of tremelimumab and durvalumab in combination versus sequentially in recurrent platinum-resistant ovarian cancer.
    Cancer. 2023 Nov 27. doi: 10.1002/cncr.35126.
    >> Share


  39. HPV testing in older women may improve cervical cancer prevention.
    Cancer. 2023;129:3518.
    >> Share

    October 2023
  40. GRITHER WR, Hagemann IS, Powell MA, Mullen MM, et al
    Attack of the clones: Unveiling subclonal/heterogenous mismatch repair (MMR)/microsatellite instability (MSI) status in endometrial cancer (EC).
    Cancer. 2023 Oct 30. doi: 10.1002/cncr.35067.
    >> Share


  41. Retraction: Yanjing Wu, Shupeng Liu, Hong Xin, Jing Jiang, Edward Younglai, Shuhan Sun, and Huilan Wang. Up-regulation of microRNA-145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells. Cancer 2011;117:3989-3998.
    Cancer. 2023 Oct 28. doi: 10.1002/cncr.35092.
    >> Share

  42. LIU YL, Gordhandas S, Arora K, Rios-Doria E, et al
    Pathogenic germline variants in patients with endometrial cancer of diverse ancestry.
    Cancer. 2023 Oct 27. doi: 10.1002/cncr.35071.
    >> Share

  43. SOROURI K, Sella T, Rosenberg SM, Loucks M, et al
    Conception and pregnancy among women with a live birth after breast cancer treatment: A survey study of young breast cancer survivors.
    Cancer. 2023 Oct 25. doi: 10.1002/cncr.35066.
    >> Share

  44. KNISELY A, Ahmed J, Stephen B, Piha-Paul SA, et al
    Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignancies.
    Cancer. 2023 Oct 21. doi: 10.1002/cncr.35063.
    >> Share

  45. FLOREZ N, Kiel L, Meza K, Wei Z, et al
    Sexual Health Assessment in Women with Lung Cancer study: Sexual health assessment in women with lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35057.
    >> Share

  46. PARK S, Kim YJ, Min YJ, Mortimer PGS, et al
    Biomarker-driven phase 2 umbrella trial: Clinical efficacy of olaparib monotherapy and combination with ceralasertib (AZD6738) in small cell lung cancer.
    Cancer. 2023 Oct 16. doi: 10.1002/cncr.35059.
    >> Share

    September 2023
  47. RIEDINGER CJ, Esnakula A, Haight PJ, Suarez AA, et al
    Characterization of mismatch-repair (MMR)/microsatellite instability (MSI)-discordant endometrial cancers.
    Cancer. 2023 Sep 26. doi: 10.1002/cncr.35030.
    >> Share

  48. NIERENGARTEN MB
    New standard of care for platinum-resistant ovarian cancer.
    Cancer. 2023;129:2601-2602.
    >> Share

  49. NIERENGARTEN MB
    Combination therapy may create a practice change for advanced or recurrent endometrial cancer: Two new studies show the value of adding immunotherapy to standardof-care chemotherapy to improve progression-free survival.
    Cancer. 2023;129:2600-2601.
    >> Share

  50. VADAPARAMPIL ST, Fuzzell LN, Brownstein NC, Fontenot HB, et al
    A cross-sectional survey examining clinician characteristics, practices, and attitudes associated with adoption of the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines.
    Cancer. 2023;129:2671-2684.
    >> Share

  51. NIERENGARTEN MB
    Not removing ovaries during benign hysterectomy: Benefits may outweigh risks.
    Cancer. 2023;129:2602.
    >> Share

  52. MACKINNON KM, Risica PM, von Ash T, Scharf AL, et al
    Barriers and motivators to women's cancer screening: A qualitative study of a sample of diverse women.
    Cancer. 2023;129.
    >> Share

    July 2023
  53. WHITE VM, Alexiadis M, Eroh KD, Ackermann MK, et al
    How social media can help to understand treatment experiences of survivors of rare cancers: Findings from the Granulosa Cell Tumor Survivor Sisters Facebook group member survey.
    Cancer. 2023;129:2224-2234.
    >> Share

  54. PRINTZ C
    Yale study finds Black patients are more likely to experience uterine cancer testing delays.
    Cancer. 2023;129:2115-2116.
    >> Share

    June 2023
  55. GRISHAM RN, Manning-Geist BL, Chui MH
    The highs and lows of serous ovarian cancer.
    Cancer. 2023 Jun 27. doi: 10.1002/cncr.34903.
    >> Share

  56. MEDINA HN, Penedo FJ, Joachim C, Deloumeaux J, et al
    Endometrial cancer risk and trends among distinct African descent populations.
    Cancer. 2023 Jun 26. doi: 10.1002/cncr.34789.
    >> Share

  57. FRANCO EL
    The time has come to implement primary human papillomavirus screening for cervical cancer in the United States.
    Cancer. 2023 Jun 22. doi: 10.1002/cncr.34899.
    >> Share

  58. MIRZA MR, Gonzalez-Martin A, Graybill WS, O'Malley DM, et al
    Prospective evaluation of the tolerability and efficacy of niraparib dosing based on baseline body weight and platelet count: Results from the PRIMA/ENGOT-OV26/GOG-3012 trial.
    Cancer. 2023;129:1846-1855.
    >> Share

    May 2023
  59. THOMAS TH, Bender C, Donovan HS, Murray PJ, et al
    The feasibility, acceptability, and preliminary efficacy of a self-advocacy serious game for women with advanced breast or gynecologic cancer.
    Cancer. 2023 May 27. doi: 10.1002/cncr.34887.
    >> Share

  60. SPENCER JC, Noel L, Shokar NK, Pignone MP, et al
    Understanding the role of access in Hispanic cancer screening disparities.
    Cancer. 2023;129:1569-1578.
    >> Share

  61. KINDLER HL, Yoo HK, Hettle R, Cui KY, et al
    Patient-centered outcomes in the POLO study of active maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer.
    Cancer. 2023;129:1411-1418.
    >> Share

    April 2023
  62. BEN-ARYE E, Lavie O, Segev Y, Samuels N, et al
    Reply to "Assessing the impacts of integrative therapies on pain and anxiety after gynecological oncology surgery".
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34803.
    >> Share

  63. XUE FS, Yang WH, Li CW
    Assessing the impacts of integrative therapies on pain and anxiety after gynecological oncology surgery.
    Cancer. 2023 Apr 13. doi: 10.1002/cncr.34805.
    >> Share

  64. AYALA-PEACOCK DN, Chino JP
    Is it time for bone marrow sparing radiation therapy to be standard of care in cervical cancer?
    Cancer. 2023 Apr 12. doi: 10.1002/cncr.34769.
    >> Share

  65. WANG S, Liu J, Lei K, Jia Y, et al
    Single-photon emission computed tomography-defined active bone marrow-sparing volumetric-modulated arc therapy reduces the incidence of acute hematologic toxicity in locally advanced cervical cancer patients who receive chemoradiotherapy: A single-cen
    Cancer. 2023 Apr 12. doi: 10.1002/cncr.34771.
    >> Share

  66. NIERENGARTEN MB
    Balancing the benefits and harms of cervical cancer screening in older women.
    Cancer. 2023;129:979-980.
    >> Share

    March 2023
  67. MANNING-GEIST BL, Kahn RM, Nemirovsky D, Girshman J, et al
    Chemotherapy response in low-grade serous ovarian carcinoma at a comprehensive cancer center: readdressing the roles of platinum and cytotoxic therapies.
    Cancer. 2023 Mar 23. doi: 10.1002/cncr.34753.
    >> Share

  68. FOSTER KI, Shaw KRM, Jin J, Westin SN, et al
    Clinical implications of tumor-based next-generation sequencing in high-grade epithelial ovarian cancer.
    Cancer. 2023 Mar 17. doi: 10.1002/cncr.34724.
    >> Share

  69. METCALFE KA, Gronwald J, Tung NM, McCuaig JM, et al
    The risks of cancer in older women with BRCA pathogenic variants: How far have we come?
    Cancer. 2023;129:901-907.
    >> Share

  70. CHINO JP, Moss HA, Swartz JJ, Gray BA, et al
    Care of the pregnant patient with cancer should include unfettered access to abortion.
    Cancer. 2023 Mar 12. doi: 10.1002/cncr.34686.
    >> Share

  71. NGUYEN T, Bhosale PR, Cassia L, Surabhi V, et al
    Malignancy in pregnancy: Multimodality imaging and treatment.
    Cancer. 2023 Mar 12. doi: 10.1002/cncr.34688.
    >> Share

  72. HENDRIKSE CSE, van der Ploeg P, van de Kruis NMA, Wilting JHC, et al
    Functional estrogen receptor signal transduction pathway activity and antihormonal therapy response in low-grade ovarian carcinoma.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34661.
    >> Share

  73. GRISHAM RN, Manning-Geist BL, Chui MH
    Beyond the estrogen receptor: In search of predictive biomarkers for low-grade serous ovarian cancer.
    Cancer. 2023 Mar 3. doi: 10.1002/cncr.34658.
    >> Share

  74. NIERENGARTEN MB
    FDA grants accelerated approval for targeted therapy for platinum-resistant gynecologic cancers.
    Cancer. 2023;129:656.
    >> Share

    February 2023
  75. HYDE ET, LaCroix AZ, Evenson KR, Howard AG, et al
    Accelerometer-measured physical activity and postmenopausal breast cancer incidence in the Women's Health Accelerometry Collaboration.
    Cancer. 2023 Feb 22. doi: 10.1002/cncr.34699.
    >> Share

    January 2023
  76. BEN-ARYE E, Segev Y, Galil G, Marom I, et al
    Acupuncture during gynecological oncology surgery: A randomized controlled trial assessing the impact of integrative therapies on perioperative pain and anxiety.
    Cancer. 2023 Jan 17. doi: 10.1002/cncr.34542.
    >> Share

  77. PODWIKA SE, Duska LR
    Top advances of the year: Cervical cancer.
    Cancer. 2023 Jan 7. doi: 10.1002/cncr.34617.
    >> Share

    December 2022
  78. KANG EY, Weir A, Meagher NS, Farrington K, et al
    CCNE1 and survival of patients with tubo-ovarian high-grade serous carcinoma: An Ovarian Tumor Tissue Analysis consortium study.
    Cancer. 2022 Dec 26. doi: 10.1002/cncr.34582.
    >> Share

    October 2022
  79. LUTGENDORF SK, Thaker PH, Goodheart MJ, Arevalo JMG, et al
    Biobehavioral factors predict an exosome biomarker of ovarian carcinoma disease progression.
    Cancer. 2022 Oct 17. doi: 10.1002/cncr.34496.
    >> Share

  80. DUSKA LR
    Overcoming disparities to improve cancer care: The story of cervical cancer.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34488.
    >> Share

  81. VIKRAMAN SM, Khanna D, Dandpat A
    Cervical cancer elimination in indian context: Moving from barriers to facilitators.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34486.
    >> Share

  82. RIMEL BJ, Kunos CA, Macioce N, Temkin SM, et al
    Current gaps and opportunities in screening, prevention, and treatment of cervical cancer.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34487.
    >> Share

  83. MARKOVINA S, Rendle KA, Cohen AC, Kuroki LM, et al
    Improving cervical cancer survival-A multifaceted strategy to sustain progress for this global problem.
    Cancer. 2022 Oct 14. doi: 10.1002/cncr.34485.
    >> Share

  84. O'ROURKE K
    First person profile: Robert C. Bast Jr MD: As an ovarian cancer expert, Dr Bast has made history by identifying cancer antigen 125, and he has shared his knowledge by mentoring the next generation of physicians: As an ovarian cancer expert, Dr Bast h
    Cancer. 2022;128:3431-3432.
    >> Share

    August 2022
  85. MCDANIELS-DAVIDSON C, Feng CH, Martinez ME, Canchola AJ, et al
    Improved survival in cervical cancer patients receiving care at National Cancer Institute-designated cancer centers.
    Cancer. 2022 Aug 2. doi: 10.1002/cncr.34404.
    >> Share

    July 2022
  86. MOUKARZEL LA, Ferrando L, Stylianou A, Lobaugh S, et al
    Impact of obesity and white adipose tissue inflammation on the omental microenvironment in endometrial cancer.
    Cancer. 2022 Jul 6. doi: 10.1002/cncr.34356.
    >> Share

    June 2022
  87. RAUH-HAIN JA, Zubizarreta J, Nitecki R, Melamed A, et al
    Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study.
    Cancer. 2022 Jun 29. doi: 10.1002/cncr.34371.
    >> Share

  88. MARTH C, Abreu MH, Andersen KK, Aro KM, et al
    Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial).
    Cancer. 2022 Jun 17. doi: 10.1002/cncr.34350.
    >> Share

  89. JAMIESON A, Barroilhet LM, McAlpine JN
    Molecular classification in endometrial cancer: Opportunities for precision oncology in a changing landscape.
    Cancer. 2022 Jun 3. doi: 10.1002/cncr.34328.
    >> Share

  90. O'ROURKE K
    Cemiplimab shines for recurrent cervical cancer.
    Cancer. 2022;128:2050-2051.
    >> Share

  91. JOUNG RH, Nelson H, Mullett TW, Kurtzman SH, et al
    A national quality improvement study identifying and addressing cancer screening deficits due to the COVID-19 pandemic.
    Cancer. 2022;128:2119-2125.
    >> Share

    May 2022
  92. NERO C, Pasciuto T, Cappuccio S, Corrado G, et al
    Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score-matched analysis.
    Cancer. 2022 May 26. doi: 10.1002/cncr.34331.
    >> Share

  93. STENZEL AE, Bustamante G, Sarkin CA, Harripersaud K, et al
    The intersection of sexual orientation with race and ethnicity in cervical cancer screening.
    Cancer. 2022 May 16. doi: 10.1002/cncr.34213.
    >> Share

  94. O'ROURKE K
    Pembrolizumab is effective for endometrial cancer.
    Cancer. 2022;128:1886-1887.
    >> Share

    April 2022
  95. O'ROURKE K
    Better HPV vaccination and cervical cancer screening needed.
    Cancer. 2022;128:1559.
    >> Share

    February 2022
  96. EKANAYAKE WEERAMANGE C, Shu D, Tang KD, Batra J, et al
    Analysis of human leukocyte antigen associations in human papillomavirus-positive and -negative head and neck cancer: Comparison with cervical cancer.
    Cancer. 2022 Feb 17. doi: 10.1002/cncr.34148.
    >> Share

  97. LU E, Hatchell KE, Nielsen SM, Esplin ED, et al
    Fumarate hydratase variant prevalence and manifestations among individuals receiving germline testing.
    Cancer. 2022;128:675-684.
    >> Share

    January 2022
  98. HENDERSON TO, Fowler BW, Hamann HA, Nathan PC, et al
    Subsequent malignant neoplasms in the Childhood Cancer Survivor Study: Occurrence of cancer types in which human papillomavirus is an established etiologic risk factor.
    Cancer. 2022;128:373-382.
    >> Share

  99. ARUN BK, Peterson SK, Sweeney LE, Bluebond RD, et al
    Increasing referral of at-risk women for genetic counseling and BRCA testing using a screening tool in a community breast imaging center.
    Cancer. 2022;128:94-102.
    >> Share

    December 2021
  100. MCBRIDE CM, Pathak S, Johnson CE, Alberg AJ, et al
    Psychosocial factors associated with genetic testing status among African American women with ovarian cancer: Results from the African American Cancer Epidemiology Study.
    Cancer. 2021 Dec 9. doi: 10.1002/cncr.34053.
    >> Share

  101. BELLONE S, Roque DM, Siegel ER, Buza N, et al
    A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.34025.
    >> Share

  102. ANTILL Y, Buchanan DD, Scott CL
    Mismatch repair and clinical response to immune checkpoint inhibitors in endometrial cancer.
    Cancer. 2021 Dec 7. doi: 10.1002/cncr.34024.
    >> Share

  103. MOMTAZ P, O'Connor CA, Chou JF, Capanu M, et al
    Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
    Cancer. 2021;127:4393-4402.
    >> Share

    November 2021
  104. PEI J, Li M, Wu C, Xu M, et al
    Worldwide trends in cervical cancer incidence and mortality.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34029.
    >> Share

  105. LIN S, Gao K, Jin M
    Reply to Worldwide trends in cervical cancer incidence and mortality.
    Cancer. 2021 Nov 24. doi: 10.1002/cncr.34031.
    >> Share

  106. TEMKIN SM, Smeltzer MP, Dawkins MD, Boehmer LM, et al
    Improving the quality of care for patients with advanced epithelial ovarian cancer: Program components, implementation barriers, and recommendations.
    Cancer. 2021 Nov 17. doi: 10.1002/cncr.34023.
    >> Share

  107. DESAI S, Zhu MJ, Lapidos-Salaiz I
    Cervical cancer prevention: Human papillomavirus testing as primary screening.
    Cancer. 2021 Nov 12. doi: 10.1002/cncr.34006.
    >> Share

    October 2021
  108. DIN HN, Strong D, Singh-Carlson S, Corliss HL, et al
    Association between pregnancy intention and preconception health behaviors.
    Cancer. 2021 Oct 11. doi: 10.1002/cncr.33958.
    >> Share

  109. BRANDT HM, Kepka D, Kirchhoff AC, Daniel CL, et al
    Human papillomavirus (HPV) vaccination is cancer prevention for childhood cancer survivors.
    Cancer. 2021 Oct 4. doi: 10.1002/cncr.33920.
    >> Share

  110. NIERENGARTEN MB
    Rucaparib is a safe and effective maintenance therapy for advanced pancreatic cancer.
    Cancer. 2021;127:3498.
    >> Share

  111. PINATTI LM, Gu W, Wang Y, Elhossiny A, et al
    SearcHPV: A novel approach to identify and assemble human papillomavirus-host genomic integration events in cancer.
    Cancer. 2021;127:3531-3540.
    >> Share

    September 2021
  112. KOTSOPOULOS J, Kim SJ, Armel S, Bordeleau L, et al
    An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.
    Cancer. 2021;127:3183-3193.
    >> Share

    August 2021
  113. SCHAEFER IM, Lundberg MZ, Demicco EG, Przybyl J, et al
    Relationships between highly recurrent tumor suppressor alterations in 489 leiomyosarcomas.
    Cancer. 2021;127:2666-2673.
    >> Share

    June 2021
  114. MAKHNOON S, Tran G, Levin B, Mattie KD, et al
    Uptake of cancer risk management strategies among women who undergo cascade genetic testing for breast cancer susceptibility genes.
    Cancer. 2021 Jun 22. doi: 10.1002/cncr.33668.
    >> Share

    March 2021
  115. BALACHANDRA S, Kusin SB, Lee R, Blackwell JM, et al
    Blood-based biomarkers of human papillomavirus-associated cancers: A systematic review and meta-analysis.
    Cancer. 2021;127:850-864.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016